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Purpose/Objective: This study is to investigate the body 
contour changes and tumor regression in intensity modulated 
radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) 
after 1-month of treatment and to identify factors associated 
with body contour changes. 
Materials and Methods: Thirty-eight newly diagnosed NPC 
patients were enrolled in this study and were treated with 
IMRT; computer-assisted tomography (CT) of head and neck 
for IMRT planning were performed twice, the 1st CT at one 
week before radiotherapy (Plan 1) and the 2nd CT at 22 
radiation treatments (Plan 2). Same physician outlined all 
target volumes and organs at risk. The physical objective and 
dose constraints were optimized with same criteria. Principle 
component analysis and clustering were used for body 
contour changes. We tried to identify variables associated 
with body contour changes before and after treatments. 
Results: Patient weight decreased remarkably after 1-month 
of radiotherapy. The average weight decreased by 3.0% 
(2.3kg, range 1.5-3.2kg). Comparing Plan 1 to Plan 2, the 
parotid gland volume was significantly reduced by 15.7% 
(10.8cc, ranged from 7.5-14.2cc); the submandibular gland 
volume by 15.8% (3.4cc, ranged from 2.14-4.65cc); GTV by 
15.5% (3.8cc, ranged from 2.4-5.3cc); and GTV-LN by 41.8% 
(15.1cc, ranged from 8.7-21.6cc). The separation distance in 
each slice of head and neck CT images reduced by average of 
0.32-0.89 cm (1.9%-6.0%), especially at the transverse 
diameter in the level of 3rd cervical spine (0.9cm). The GTV 
volume on average shrank 2.23cc and 6.91 cc as comparing 
T1-3 with T4 disease (p = 0.0013); The GTV-LN volume shrank 
on average 8.59 cc, 38.93 cc (p = 0.0208) as comparing N1-2 
with N3 disease. The transverse diameter changes of head 
and neck contours were correlated significantly with N stage 
and body weight loss. 
Conclusions: For NPC patients treated with IMRT, weight 
loss, volume reduction of salivary gland and body contour 
changes are common. The salivary glands on average reduced 
volume by 16% and GTV-LN by 42% after one-month 
treatment. The most significant factor associated with body 
contour changes is weight loss. We recommend repeat 
simulation after one-month of radiotherapy in order to 
reduce the dose to the normal organs and avoid missing 
treatment targets. 
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Purpose/Objective: To retrospectively assess the loco-
regional disease control in head-and-neck cancer (HNC) 
patients treated with Intensity Modulated Radiation Therapy 
(IMRT) and estimate the role of treatment plan dosimetry as 
a predictor for loco-regional control (LC). 
Materials and Methods: Between February 2012 and February 
2014, 30 consecutive patients with HNC were treated with 
Simultaneous Integrated Boost (SIB) IMRT. Their demographic 
and clinical variables, such as age at the time of diagnosis, 
gender, T and N stage and chemotherapy data were collected 
and analyzed. Planning CT images of all patients with loco-
regional failures were retrospectively reviewed and 
dosimetric data of the treatment plans investigated, seeking 
for a possible correlation between an eventual loco-regional 
disease relapse and the dose delivered to the area where the 
relapse occurred. Dose-Volume-Histograms (DVH) were used 
to extract D95%, D98% and Dmean values. Because DVH does not 
provide spatial information about hot and cold spots, 
Equivalent Uniform Dose (EUD) was considered too. As the 
dose varied among patients, for analysis we used values of 
D95%, D98%, Dmean and EUD normalized to the prescribed dose. 
Correlation of the available variables with LC was assessed by 
a logistic regression test and a p value of < 0.05 was 
considered significant. 
Results: After a median follow-up of 12 months (range: 1-28 
months), 8 (26%) patients presented loco-regional relapse and 
22 (64%) were free of disease. During this time, 3 (10%) 
patients died from the disease; all of them were tongue 
cancer cases. 
Table 1. Patient and tumor characteristics (n=30). 
 
 
Significantly improved LC of the disease was associated with 
nasopharyngeal diagnosis (p=0.0004), early stages (T1, 
p=0.0454; N0, p=0.0024), and the use of concomitant 
chemotherapy (p=0.0028).  
Treatment plans evaluation showed that all loco-regional 
relapses occurred within the 95% isodose line inside the 
Planning-Target-Volume (PTV) of the primary disease. 
Dosimetric parameters analysis showed a weak correlation 
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between LC and D95% and D98%, but a strong dependence on 
Dmean (p=0.0274) and EUD (p=0.0483) was noticed. 
Fig. 1. The correlation between loco-regional control and D95% 
(a), D98% (b), Dmean (c) and EUD (d). Values of D95%, D98%, Dmean 
and EUD are normalized to the prescribed dose. 
 
a. 
 
b. 
 
 
c. 
 
d. 
 
 
Due to the small number of patients, multivariate analysis of 
correlation between LC and patients' clinical and dosimetric 
data was not possible, and further studies are needed to 
identify the most predictive variable. 
Conclusions: LC for HNC patients treated with SIB IMRT 
significantly correlates with pathology, stage and the use of 
concomitant chemotherapy.  Treatment plan dosimetric data 
such as Dmean and EUD appear to be useful predictors of LC for 
this group of patients. 
   
 
 
 
EP-1138   
Reirradiation, cetuximab and itraconazole in locally 
recurrent and unresectable head and neck cancer 
D. Milanovic1, A.L. Grosu1, M. Henke1 
1Universitätsklinik Freiburg, Department of Radiation 
Oncology, Freiburg, Germany  
 
Purpose/Objective: Locoregional inoperable recurrence of 
previously irradiated head and neck carcinoma (HNC) remain 
a therapeutic challenge. In our previous study, we combined 
re-RT with cetuximab, with the aim to inhibit epidermal 
growth factor receptor EGFR and consequently increase 
tumor radiosensitivity, but this therapeutic approach did not 
influence patient survival in the comparison to standard 
therapy. Hedgehog (HH) signaling pathway, which plays 
important role in embryogenesis, carcinogenesis und 
radioresistance, can mediate therapeutic resistance to EGFR 
targeted therapies. Itraconazole is well known antimicotic 
agent which inhibits HH signaling. In patients with advanced 
basal cell carcinoma, itraconazole inhibited this pathway and 
caused promising clinical response. We propose that 
inhibition of HH signaling with itraconazole will avoid 
development of resistance to cetuximab and that 
simultaneous inhibition of these two pathways which 
interfere with radioresistance may lead to better tumor 
response and consequently prolonged survival in patient with 
recurrent HNC treated with re-RT. 
Materials and Methods: Between March and November 2014, 
we reirradiated (59.4 Gy, 5 X 1.8 Gy/Week) 5 patients with 
inoperable, previously irradiated, recurrent HNC. Cetuximab 
was given initially at 400 mg/m2 two days prior to re-RT and 
weekly (250 mg/m2) thereafter. Patients were treated with 
first dose itraconazole (100 mg) two days prior to re-RT and 
continued to take this drug daily two weeks after finishing re-
RT.  
Results: Itroconazole did not increase toxicity of re-RT and 
cetuximab expecting for induction of acne-like skin rash. 3 
patients developed grade III and 1 grade II of this 
complication. Until now, three patients had a first follow-up 
investigation – two partial responses (1 patient with grade I 
and one with grade III skin rash) and 1 with grade III and one 
stable disease were documented. 
Conclusions: Promising antitumor responses were observed. 
To determine if this therapeutic strategy may influence 
survival in patients with recurrent HNC treated with re-RT, 
larger clinical studies are necessary.  
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Purpose/Objective: To evaluate the efficacy and toxicity in a 
group of patient with non-metastatic nasopharyngeal 
carcinoma (NPC) treated with a hypofractionated radiation 
therapy with or without chemotherpy. 
